Matthew Gline, CEO at Roivant Sciences Ltd. (ROIV), sold 4,475,998 shares at $11.79 ($52.9M) on 2024-09-23, disclosed to the SEC on 2024-09-24.
Scheduled sale ($52.9M) by CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $11.97 | 10,945 | $131K | 0.2% |
| 2 | $11.79 | 1,983,257 | $23.4M | 44.2% |
| 3 | $11.79 | 1,983,257 | $23.4M | 44.2% |
| 4 | $11.97 | 498,539 | $6.0M | 11.3% |
| Total | $11.81 avg | 4,475,998 | $52.9M | 100% |
| Filing → |
| ROIV | BUY | 2025-09-18 | $50K | — | Filing → |
| ROIV | SELL | 2022-10-27 | $170K | — | Filing → |
| ROIV | SELL | 2022-09-27 | $129K | — | Filing → |